HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice

• Published in: International journal of molecular sciences Vol. 25; no. 13; p. 7475
• Main Authors: Albert, Veruschka, Bruss, Christina, Tümen, Deniz, Piendl, Gerhard, Weber, Florian, Dahl, Edgar, Seitz, Stephan, Ortmann, Olaf, Wege, Anja K, Brockhoff, Gero
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 08.07.2024
• Subjects: abemaciclib; Aminopyridines - pharmacology; Aminopyridines - therapeutic use; Animals; Benzimidazoles - pharmacology; Benzimidazoles - therapeutic use; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cell cycle; Cell death; Cell growth; Cell Line, Tumor; Cell Proliferation - drug effects; Cloning; CRISPR; Drug Resistance, Neoplasm - genetics; Estrogens; Female; Flow cytometry; Gene amplification; Growth factors; hormone receptor positive (HR+) breast cancer; human epidermal growth factor receptor related (HER4); humanized tumor mice (HTM); Humans; Kinases; Ligands; MCF-7 Cells; Mice; Proteins; Receptor, ErbB-4 - genetics; Receptor, ErbB-4 - metabolism; tamoxifen; Tamoxifen - pharmacology; Tamoxifen - therapeutic use; Xenograft Model Antitumor Assays; hormone receptor positive (HR+) breast cancer; human epidermal growth factor receptor related (HER4); humanized tumor mice (HTM); tamoxifen; abemaciclib
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25137475

The impact of the HER4 receptor on the growth and treatment of estrogen receptor-positive breast cancer is widely uncertain. Using CRISPR/Cas9 technology, we generated stable HER4 knockout variants derived from the HER4-positive MCF-7, T-47D, and ZR-75-1 breast cancer cell lines. We investigated tumor cell proliferation as well as the cellular and molecular mechanisms of tamoxifen, abemaciclib, AMG232, and NRG1 treatments as a function of HER4 in vitro. HER4 differentially affects the cellular response to tamoxifen and abemaciclib treatment. Most conspicuous is the increased sensitivity of MCF-7 in vitro upon HER4 knockout and the inhibition of cell proliferation by NRG1. Additionally, we assessed tumor growth and immunological effects as responses to tamoxifen and abemaciclib therapy in humanized tumor mice (HTM) based on MCF-7 HER4-wildtype and the corresponding HER4-knockout cells. Without any treatment, the enhanced MCF-7 tumor growth in HTM upon HER4 knockout suggests a tumor-suppressive effect of HER4 under preclinical but human-like conditions. This phenomenon is associated with an increased HER2 expression in MCF-7 in vivo. Independent of HER4, abemaciclib and tamoxifen treatment considerably inhibited tumor growth in these mice. However, abemaciclib-treated hormone receptor-positive breast cancer patients with tumor-associated mdm2 gene copy gains or pronounced HER4 expression showed a reduced event-free survival. Evidently, the presence of HER4 affects the efficacy of tamoxifen and abemaciclib treatment in different estrogen receptor-positive breast cancer cells, even to different extents, and is associated with unfavorable outcomes in abemaciclib-treated patients.